TNFSF11 and urinary tract infection: Denosumab therapy in KTRs necessitates vigilant monitoring for infection risks, particularly urinary tract infections, since immunosuppressed patients may experience increased susceptibility to infections due to the dual impact of RANKL inhibition on immune cell development and ongoing immunosuppressive therapy.